{"id":"https://genegraph.clinicalgenome.org/r/981bf8d6-a559-4345-aa07-2d81b92fe58bv1.1","type":"EvidenceStrengthAssertion","dc:description":"CASQ2 was evaluated for autosomal recessive catecholaminergic polymorphic ventricular tachycardia (CPVT). Biallelic loss-of-function variants in CASQ2 (homozygous and compound heterozygous) have been reported in numerous CPVT probands, including frameshift, nonsense and splice donor/acceptor variants, as well as other splice region variants with verified effects on splicing and missense variants with verified loss-of-function effects (Postma et al, 2002, PMID:12386154; di Barletta et al, 2006, PMID:16908766; Roux-Buisson et al, 2011, PMID:21618644). Additional genetic evidence comes from the segregation of the homozygous p.Asp307His variant with CPVT in a large family from Israel (LOD score = 8.2), which is highly likely to be the causative variant even though not every gene in the linked region was sequenced (Lahat et al, 2004, PMID:15176429). The association of CASQ2 with autosomal recessive CPVT is also supported by a plethora of experimental evidence, including functional alteration, non-human model organism, and rescue in non-human model organism. Most of this evidence has been generated from CASQ2 knockout mice and knock-in mice for variants detected in CPVT patients (di Barletta et al, 2006, PMID:16908766; Dirksen et al, 2007, PMID:17449018; Song et al, 2007, PMID:17607358; Rizzi et al, 2008, PMID:18583715). AAV-mediated injection of CASQ2 in knockout and p.Asp307His mice has been shown to at least partially rescue the CPVT phenotype (Kutzwald Josefson et al, 2017, PMID:28336343). Additional evidence is available in the literature, but the maximum score for genetic evidence and experimental evidence has been reached. In summary, CASQ2 variants are definitively associated with autosomal recessive CPVT. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. Note: All CPVT genes were curated by 3 separate blinded teams. The evidence and scores reached by these 3 teams was reviewed by the CPVT Gene Curation Expert Panel (GCEP). The classification and summary presented here is the conclusion of this GCEP's analysis according to evidence teams' efforts. This classification was approved by the ClinGen Catecholaminergic Polymorphic Ventricular Tachycardia Gene Curation Expert Panel on 20th January, 2021 (SOP Version 7).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/981bf8d6-a559-4345-aa07-2d81b92fe58b","GCISnapshot":"https://genegraph.clinicalgenome.org/r/6e7525b5-98fa-4116-9413-15be8d5e87d3","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/6e7525b5-98fa-4116-9413-15be8d5e87d3_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10074","date":"2021-04-22T19:08:35.699Z","role":"Unpublisher"},{"id":"https://genegraph.clinicalgenome.org/r/991ee32e-280d-4bea-a638-aa1b6fa6f781_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10074","date":"2021-04-22T19:08:35.699Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/991ee32e-280d-4bea-a638-aa1b6fa6f781_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10074","date":"2021-01-20T17:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/991ee32e-280d-4bea-a638-aa1b6fa6f781_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c1348345-ee33-434a-8445-ffa0f9b51588_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3ebf7d1d-8fe3-46c8-8c0d-1c9d49e5b17d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21618644","rdfs:label":"Family 3: I-1","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0001279","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/c1348345-ee33-434a-8445-ffa0f9b51588_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21618644","allele":[{"id":"https://genegraph.clinicalgenome.org/r/6258acf4-2434-4311-b24c-7d7ccec6125f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001232.3(CASQ2):c.164A>G (p.Tyr55Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341767114"}},{"id":"https://genegraph.clinicalgenome.org/r/030d4bc9-7b89-4493-aa88-f899046771a8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001232.4(CASQ2):c.603del (p.Val203LeufsTer7)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139770956"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/fbb517e3-957b-47d1-95ec-71afcee0e671_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b11b6486-6438-4354-8f9f-f2a8d3a4ee0d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21618644","rdfs:label":"Family 2: III-3","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0001279","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/fbb517e3-957b-47d1-95ec-71afcee0e671_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21618644","allele":{"id":"https://genegraph.clinicalgenome.org/r/73b5c46f-c5d5-4956-b522-854a96ee28de","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000001.11:g.115702920C>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341766565"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/991ee32e-280d-4bea-a638-aa1b6fa6f781_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f6d4b9dd-4b90-48db-8acc-e721a71f6ebc_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11401939","rdfs:label":"Family 1","family":{"id":"https://genegraph.clinicalgenome.org/r/f6d4b9dd-4b90-48db-8acc-e721a71f6ebc","type":"Family","rdfs:label":"Family 1","ethnicity":{"id":"cg:NotHispanicOrLatino"}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":13,"publishedLodScore":8.24,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/7fbbde51-6d9c-4ffd-bbd3-6e58612013ee_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e6cf46e-45c4-4b17-81a8-18c468f57299","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21618644","rdfs:label":"Family 1: III-3","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001279","obo:HP_0031628"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7fbbde51-6d9c-4ffd-bbd3-6e58612013ee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21618644","allele":{"id":"https://genegraph.clinicalgenome.org/r/1ad156ee-f89e-44de-9f66-d381d082583d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000001.11:g.115740830T>C (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341764557"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7a3af45c-ef8a-4d38-8b75-8ab58cdc132d_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/423f647c-5f12-41c5-b2c9-a50b5186844b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16908766","rdfs:label":"Family 2: III-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":17,"detectionMethod":"The 11 exons of CASQ2(GenBank: NM_001232) were amplified with intronic primers and analyzed by denaturing high-performance liquid chromatography. Abnormal elution profiles were sequenced.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":"obo:HP_0004758","previousTesting":true,"previousTestingDescription":"The coding region of the RyR2gene was amplified by polymerase chain reaction (PCR) with intronic primers10 and analyzed by the single-strand conformation polymorphism method.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/7a3af45c-ef8a-4d38-8b75-8ab58cdc132d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16908766","allele":[{"id":"https://genegraph.clinicalgenome.org/r/cae4e9c9-be2a-48dd-8939-af9d7d44ea48","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001232.3(CASQ2):c.500T>A (p.Leu167His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA258048"}},{"id":"https://genegraph.clinicalgenome.org/r/4281d444-d5a7-4965-a108-c2d6cffad9d1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001232.4(CASQ2):c.339_354del (p.Ser113ArgfsTer6)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/17611"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/5ff1b7ab-22bc-4139-b3a2-d1b5234dc93f_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bb7538f6-6c75-4bd0-bd50-5b83b42f0e8e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12386154","rdfs:label":"Family 1: II-2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"detectionMethod":"Direct sequencing of all coding regions of CASQ2.","firstTestingMethod":"PCR","phenotypes":"obo:HP_0004758","previousTesting":true,"previousTestingDescription":"Direct DNA sequencing of all protein-coding areas of the candidate genes, HRC, and PLN and sequencing of 50% of the RyR2 gene failed to reveal any mutations. The proband’s coding regions of KCNQ1, KCNE1, KCNH2, KCNK1, and SCN5A did not reveal any abnormal conformers by PCR-single-strand conformation polymorphism screening.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/5ff1b7ab-22bc-4139-b3a2-d1b5234dc93f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12386154","allele":{"id":"https://genegraph.clinicalgenome.org/r/91737bba-b5d1-4faa-9068-9cf158c2c1cb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001232.4(CASQ2):c.62del (p.Glu21GlyfsTer15)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/41042"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/2dfbf0ea-e0b7-40ef-9d7a-9dd123f23c8c_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c911df00-a139-484c-a185-e02d1d57af16","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12386154","rdfs:label":"Family 2: III-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"detectionMethod":"Direct sequencing of all coding regions of CASQ2.","firstTestingMethod":"PCR","phenotypes":["obo:HP_0000980","obo:HP_0002789","obo:HP_0005184","obo:HP_0000961","obo:HP_0004758"],"previousTesting":true,"previousTestingDescription":"Direct DNA sequencing of all protein-coding areas of the candidate genes, HRC, and PLN and sequencing of 50% of the RyR2 gene failed to reveal any mutations.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2dfbf0ea-e0b7-40ef-9d7a-9dd123f23c8c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12386154","allele":{"id":"https://genegraph.clinicalgenome.org/r/078fcbb7-afbb-4bb7-8aaa-4573c6d31c89","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001232.4(CASQ2):c.532+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341763774"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7da8c0e5-86fb-4808-8423-7732c4da7c4b_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/52ce37f6-869c-4b42-997c-0f590759f807","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16908766","rdfs:label":"Family 1: III-2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"detectionMethod":"The 11 exons of CASQ2 (GenBank: NM_001232) were amplified with intronic primers and analyzed by denaturing high-performance liquid chromatography. Abnormal elution profiles were sequenced.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":"obo:HP_0004758","previousTesting":true,"previousTestingDescription":"As part of this study, the coding region of the RyR2 gene was amplified by polymerase chain reaction (PCR) with intronic primers10 and analyzed by the single-strand conformation polymorphism method.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7da8c0e5-86fb-4808-8423-7732c4da7c4b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16908766","allele":{"id":"https://genegraph.clinicalgenome.org/r/4281d444-d5a7-4965-a108-c2d6cffad9d1"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/55a8fa09-444a-4281-a90d-c691f40498e7_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bbf2b57d-6015-459a-84be-ad1a3edbe25b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21618644","rdfs:label":"Family 5: II-3","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001279","obo:HP_0031628"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/55a8fa09-444a-4281-a90d-c691f40498e7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21618644","allele":[{"id":"https://genegraph.clinicalgenome.org/r/cfa40295-f166-45ff-b78c-735b41003de3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000001.11:g.115726991C>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1023812"}},{"id":"https://genegraph.clinicalgenome.org/r/7c68e911-7f15-4f9f-ad03-220008e8bf89","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000001.11:g.115705187C>G (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1023689"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/28d0de87-0b91-47fb-b6c9-a2d61dc1132a_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/85e7f9f8-58f4-47d9-86db-52f3450c3cb2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21618644","rdfs:label":"Family 4: II-3","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0001279","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/28d0de87-0b91-47fb-b6c9-a2d61dc1132a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21618644","allele":[{"id":"https://genegraph.clinicalgenome.org/r/2d7471ea-79bc-4216-944e-7d6192a9844f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001232.3(CASQ2):c.381C>T (p.Gly127=)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/801535"}},{"id":"https://genegraph.clinicalgenome.org/r/9816db6a-0d92-439d-967d-18c446eab1be","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001232.3(CASQ2):c.546del (p.Phe182fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA351370"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/991ee32e-280d-4bea-a638-aa1b6fa6f781_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/991ee32e-280d-4bea-a638-aa1b6fa6f781_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/82dca5e2-540d-40a1-9ff0-d61ad508cf0a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8023221d-37f0-42f2-b9a7-85cb318a65c8","type":"Finding","dc:description":"RNA-seq","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24309898","rdfs:label":"Analysis of Human-Tissue Specific Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/15c217d4-ee90-4677-841f-12464beba6da","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e789eb9-cef5-4d8b-b8b3-2d6304ae28c2","type":"Finding","dc:description":"Calsequestrin (CASQ2) regulates RyR2 activity directly via protein-protein interactions.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9287354","rdfs:label":"CASQ2 protein interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/991ee32e-280d-4bea-a638-aa1b6fa6f781_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9802d0d5-6f30-412b-acc4-5b0f0226f670","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bc0434e6-7f63-4cc2-8715-3def84565e69","type":"FunctionalAlteration","dc:description":"Rat ventricular myocytes were transfected with CASQ2 WT and expressing the two variants p.Ser113fs and p.L167H. After the application of caffeine, expression of the two variants reduced the Ca2+ content of the SR, compared to naive cells and cells expressing WT CASQ2  (page 1015, table 1). Expression of the two variants p.Ser113fs and p.L167H causes a significant decrease in the amplitude of Ca2+ transients. Saponin-permeabilized myocites overexpressing the 2 mutations showed a decreased magnitude of Ca2+ sparks, duration of the rising phase of sparks and spatiotemporal spread of sparks. Paced myocites overexpressing the p.Ser113fs mutations exposed to isoprotenerol exhibited spontaneous extrasystolic Ca2+ elevations and DADs (page 1016, fig 4, table 2).\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16908766","rdfs:label":"Rat ventricular myocytes - p.Ser113fs and p.L167H"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/76119c00-efaf-4131-963d-7613b8cd5d8e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/68f5aad6-4f7e-45bc-a807-f106dc325602","type":"FunctionalAlteration","dc:description":"Patch clamp experiments on mice myocytes transgenic for the D307H mutation of CASQ2: mutated cells have smaller Ca2+ transients and reduced Ʈdecay. After isoprotenerol treatment, the amplitude of Ca2+ current-induced Ca2+ transient was reduced. Isoprotenerol and caffeine administration caused extra systolic, spontaneous Ca2+ transients, occasional generation of action potentials and DADs (delayed afterdepolarizations).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17449018","rdfs:label":"D307H in mouse ventricular myocytes"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/526963da-f000-41a7-9832-2dea2c069829","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/52e224dd-3601-4029-8ddf-df264a82b85d","type":"FunctionalAlteration","dc:description":"CASQ2 R33Q/R33Q isolated mice myocytes showed a reduction of the SR Ca2+ content, adrenergically mediated delayed and early afterdepolarization leading to triggered activity.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18583715","rdfs:label":"R33Q in mice ventricular myocytes"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/991ee32e-280d-4bea-a638-aa1b6fa6f781_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b14efcb0-4ca0-4d6f-99ec-67b04cd32c47","type":"EvidenceLine","dc:description":"Phenotype not entirely convincing.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7763aa9d-a08f-41ec-9629-117033c48df0","type":"Finding","dc:description":"Expressing ≥33% of the normal CASQ2 level was needed to protect from nonsustained VT as well as stress-induced premature ventricular contractions.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28336343","rdfs:label":"AAV-CASQ2 rescue of KO and D307H mice","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c131ffb0-ff02-4cf7-95b2-70c26f1d2be8","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/89b5586d-8216-4631-b277-50f542dfbf30","type":"Finding","dc:description":"Trangenic mice expressing the D307H mutation of CASQ2. Echocardiography showed normal cardiac chamber and contractility (fig. 3). After challenge with isoprotenerol and/or caffeine they developed significantly more supraventricular and junctional ectopic beats compared to WT. Increased number of simple ventricular arrhytmias after drug challenge compared to age-matched WT mice (fig. 6)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17449018","rdfs:label":"D307H transgenic mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/8e4e5d3a-e514-480f-8acb-7c645f27cb65","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e6c71e75-fd96-4f55-b304-04ee9a83481f","type":"Finding","dc:description":"Study performed on CASQ2307/307 and CASQ2ΔE9/ΔE9 mice. No structural differences with WT mice at 15 weeks of age; at 35 weeks LV hypertrophy and reduced ejection fraction. Compared to WT and heterozygous mutant mice, CASQ2307/307 and CASQ2ΔE9/ΔE9 mice have slower resting heart rates, multiple arrhythmias during ECG recordings (ventricular premature beats, nonsustained VT, ventricular bigeminy). All showed stress induced (cathecholamines) arrhythmias. (Tab 1, fig 3-4).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17607358","rdfs:label":"D307H and ΔE9 transgenic mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/e8f26531-ba47-41fe-8edb-661e0b015c2c","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b3adb125-42b1-405e-a774-2a36575de1c7","type":"Finding","dc:description":"ECG of R33Q mice during stimuli shows VT","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18583715","rdfs:label":"R33Q/R33Q Knock-in Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":2689,"specifiedBy":"GeneValidityCriteria7","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/m54vHdeqc-o","type":"GeneValidityProposition","disease":"obo:MONDO_0017990","gene":"hgnc:1513","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_6e7525b5-98fa-4116-9413-15be8d5e87d3-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}